Isavuconazole as an optimal treatment option for multiple pathogens induced severe pneumonia in immunocompromised hosts: a case series report
BackgroundTreating severe pneumonia caused by multiple pathogens in immunocompromised hosts (ICHs) presents significant challenges.Isavuconazole (ISA), a next-generation triazole antifungal agent, has shown promise in managing fungal infections.However, clinical evidence regarding its efficacy in cases of complex infections involving multiple patho